Kornimate/medical-research-clean huggingface dataset:
effects of creatine supplementation on renal function

Conditions: Renal Insufficiency

Summary: creatine (cr) supplementation is commonly used by athletes. however, its effects on renal function remain controversial. the aim of this study was to evaluate the effects of creatine supplementation on renal function and oxidative stress in healthy sedentary males (18-35 years old) submitted to exercise training. our hipothesis is that creatine supplementation does not affect renal function in this population.

creatine (cr) supplementation is commonly used by athletes. however, its effects on renal function remain controversial. purpose: the aim of this study was to evaluate the effects of creatine supplementation on renal function and oxidative stress in healthy sedentary males (18-35 years old) submitted to exercise training. methods: subjects (n = 18) were randomly divided in two groups and were allocated to receive treatment with either creatine (cr) (\~10g • day-1 over three months) or placebo (pl) (dextrose). all subjects undertook moderate intensity aerobic training, in three 40-minute sessions per week, during 3 months. serum creatinine, tbars, serum and urinary sodium and potassium were determined at baseline and at the study endpoint. furthermore, cystatin c was also assessed prior to training (pre), after 4 (post 4) and 12 weeks (post 12). results: there were decreased in both oxidative stress (evaluated by tbars - µm/24 h) (pre cr: 8.2  4.4; pl: 6.4  0.8 vs. post 12 cr: 2.5  1.8; pl: 2.1  1.6, p=0.0001) and cystatin c levels (mg/l) (pre cr:0.82  0.09; pl: 0.88  0.07 vs. post 12 cr: 0.71  0.06; pl: 0.75  0.09, p=0.0001) over the time, suggesting an increase in glomerular filtration rate. there were no significant differences between groups in other renal parameters investigated. conclusions: these data indicate that high-dose creatine supplementation throughout three months does not provoke renal dysfunction in sedentary healthy males urdergoing aerobic training. moreover, our results suggest that moderate aerobic training per se could improve renal function.

Eligibility criteria:
inclusion criteria: * sedentary healthy males, * euthrofic, * age beteween 18-35 y exclusion criteria: * food supplement users, * pre-existing renal dysfunction, * pre-existing cardioavascular disease, * subjetcs physically active or athletes, * obesity, * drugs users
computed tomography (ct) guided lung biopsy with plug

Conditions: Computed Tomography, Biopsy, Pneumothorax, Chest Tube, Plug

Summary: protocol title: computed tomography (ct) guided lung biopsy with biosentry plug, evaluation of safety and efficacy.

protocol summary: prospective, randomized, controlled, unblinded, post-market, single-center clinical study objectives: patients treated with the biosentry system will be compared to patients not treated with the biosentry system (control group). primary objective: evaluate the rate of chest tube placement after percutaneous transthoracic needle lung biopsy secondary objectives: evaluate the rate of intra-procedural pneumothorax evaluate the rate of post-procedural pneumothorax evaluate cost associated with complications evaluate the number of hospital admissions

Eligibility criteria:
inclusion criteria: 1. provide written informed consent prior to any study related procedure 2. male or female, aged ≥18 years or older 3. percutaneous transthoracic needle lung biopsy indicated exclusion criteria: there are no specific exclusion criteria for the study. all participants are evaluated by a pulmonologist prior to admission and determined eligible for the procedure.
plethismographic perfusion index in neonates

Conditions: Patent Ductus Arteriosus; Persistent Pulmonary Hypertension of the Newborn

Summary: photoplethismography will be measured and compared in newborns suffering from patent ductus arteriosus and normal controls.

newborn babies admitted to the nicu and well baby will be connected to a specially designed photoplethismograph (ppg). right hand (pre ductal), and and one of the legs (postductal) values will be compared, based on the formula delta amplitude of ppg / baseline absorption (perfusion index (pi)). normal values will be defined in healthy term and preterm babies, and clinical conditions in which the pi is expected to change (patent ductus artheriosus, persistent pulmonary hypertension of the newborn)will be compared with these normal values.

Eligibility criteria:
inclusion criteria: * pda, pphn and normal babies who underwent echocardiography exclusion criteria: * other cardiac diseases
hypertonic saline for outpatient bronchiolitis

Conditions: Bronchiolitis; Respiratory Distress

Summary: we will study if small children who become ill with respiratory distress during the rsv epidemic are better relieved with salbutamol nebulizations diluted in hypertonic (3%), instead of normal (0.9%) saline.

in santiago, chile, a near collapse of health services is a notorious feature of every winter when vast numbers of small children line for attention because of respiratory distress caused by a probable rsv infection. our study will examine if nebulized salbutamol diluted in hypertonic (3%), instead of normal (0.9%) saline, provides better relief in outpatients. if hypertonic saline proves safe and effective, the patients could be better managed and the pressure for attention diminished at a low cost, by a simple change in the saline ampule.

Eligibility criteria:
inclusion criteria: 1. age 1 to 24 months 2. mild to moderate respiratory distress (tal score below 9) 3. up to 5 days of respiratory symptoms, including today 4. expiratory wheezing heard on chest auscultation 5. indication of salbutamol nebulization treatment by attending physician exclusion criteria: 1. two prior episodes of wheezing 2. premature birth (below 38 weeks), if below 6 months of age 3. lobar pneumonia 4. body temperature above 38 degree celsius 5. use of salbutamol during the previous 6 hours 6. pulse oxymetry reading below 90% 7. congenital heart disease 8. chronic pulmonary disease: asthma, cystic fibrosis, bronchopulmonary dysplasia 9. other chronic or genetic condition or disease

Keywords: bronchiolitis, respiratory distress, hypertonic saline
effectiveness of self-posturotherapy on the elimination of residual fragments after treatment of lower calyx urinary stones by extracorporeal lithotripsy or retrograde flexible ureteroscopy.

Conditions: Stone, Kidney

Summary: the main objective of this study is to evaluate the effectiveness of an auto posturotherapy technique on the rfs at three months of patients treated for lower calyceal urinary stones by extracorporeal lithotripsy (ecl) or retrograde flexible ureteroscopy.


Eligibility criteria:
pré inclusion criteria: * patient having read and signed the consent form for participation in the study • patient candidate for an intervention on a lower calyx stone \<15mm by lec or urss patients meeting all of the following criteria may be definitively included in the study: * patient treated by lec, or patient treated by urss and for whom the presence of lower calyceal fragments has been observed by endoscopy * absence of jj stent (patients for whom a jj stent was implanted after urss or before lec may be included as soon as it is removed) exclusion criteria: * patients presenting one of the following criteria will not be included in the study: * renal or ureteral malformation: ureteral stenosis, pyelo-ureteral junction syndrome, horseshoe kidney, para calyceal diverticulum, pelvic kidney. * lec session interrupted due to treatment intolerance * physical disability making posturotherapy impossible (particularly spinal, etc.), morbid obesity, major gastroesophageal reflux, heart or respiratory failure. * balance disorder which would not allow self-posturotherapy to be carried out alone. * patient under legal protection, under guardianship or under curatorship * posturotherapy carried out while wearing a jj probe * posturotherapy carried out by a third party (physiotherapist or other) * pregnant or breastfeeding patient * patient not affiliated to the french social security system * impossibility of providing the subject with informed information and/or giving written informed consent: dementia, psychosis, disorders of consciousness, non-french speaking patient * treatment that may modify the clearance of fragments (beta blocker, diuretic, etc.) * patient included in another therapeutic study protocol
clinical trial of psori-cm01（yxbcm01） granule to treat stable plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the purpose of this study is to evaluate the efficacy and safety of chinese herbal psori-cm01（yxbcm01） granule for stable plaque psoriasis, with blood stasis syndrome of chinese medicine.

psoriasis is an immune-abnormal, chronic, proliferative skin disease characterized by scaly, erythematous patches and papules. an epidemiological survey found chinese prevalence showed an upward trend in recent years. the disease has great influence on patients' appearance,health and quality of life. some chinese herbal medicine (chm) therapies have shown long lasting therapeutic effect on controlling psoriasis vulgaris and with minimal side effects.chm can alleviate the symptoms effectively,and reduce the recurrence rate of diseases. psori-cm01（yxbcm01）granule is one kind of chm which is observed effective and safe to treat stable stable plaque psoriasis with blood stasis syndrome in clinical practice.

Eligibility criteria:
inclusion criteria: 1. stable plaque psoriasis, duration \> 1 year. 2. patients with chinese medicine blood stasis syndrome. (2)18 to 65 years old, male or female patient. 3. mild psoriasis:3\<pasi≤10, and bsa≤10%. 4. informed consent. exclusion criteria: 1. guttate psoriasis, inverse psoriasis or exclusively involves the face; 2. acute progression of psoriasis, and erythroderma tendency.not blood stasis syndrome.not stable psoriasis. 3. pregnant, lactating, or which one plan to become pregnant in a year; 4. sas（self-rating anxiety scale）\> 50 or sds（self-rating depression scale）\> 53, or with other psychiatric disorders; 5. with history of cardiovascular, respiratory, digestive, urinary, and hematologic disease, which can't controlled through common treatment. either with cancer, infection, electrolyte imbalance, acid-base disturbance and calcium metabolic disorder. 6. allergic to any medicine or ingredients used in this study. 7. participating other clinical trials or participated within 1 month. 8. topical treatments (i.e. corticosteroids, retinoic acid) within 2 weeks; systemic therapy or phototherapy (uvb and puva) within 4 weeks; biological therapy within 12 weeks. 9. patients need systemic treatment prescribed by doctors.

Keywords: stable plaque psoriasis
cognitive behaviour therapy for sleep problems in children with autism spectrum disorder

Conditions: Autism Spectrum Disorder; Cognitive Behaviour Therapy

Summary: sleep disturbance is very common in children with autism spectrum disorder (asd),and closely associated with their core symptom, social deficit.this trial investigates the effects of cognitive behaviour therapy for insomnia (cbt-i) in children with autism spectrum disorder with sleep problems through synchronized eye-tracking and functional near-infrared spectroscopy (fnirs). this is a 1:1 parallel single-blind randomized controlled trial.

sleep disturbance is significantly associated with social deficit of asd and but the congnitive-neural mechanism underlying this association remains unclear. cognitive behaviour therapy for insomnia (icbt-i) is considered as an evidence-based treatment for insomnia. after 5 consecutive sleep interventions is a 2-year following up study, the above issue is further tested with emphasis on progressive trajectory from a developmental perspective. we examine the influence of sleep disturbance on face processing and neural response during naturalistic social behavior of asd children using synchronized eye-tracking and functional near-infrared spectroscopy (fnirs) to uncover the neural mechanism for that sleep disturbance influences social deficit.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria for autism dsm-5 and ados-2; 2. age 24months to 59months s old; 3. willing to participate in this study, and can complete the following assessments at the specific time. exclusion criteria: exclusion of severe respiratory diseases, schizophrenia, epilepsy and other brain diseases;
inchange - nintedanib for changes in cough and dyspnea in patients suffering from chronic fibrosing interstitial lung disease with a progressive phenotype in everyday clinical practice: a real-world evaluation

Conditions: Lung Diseases, Interstitial

Summary: the primary objective of this study is to investigate the correlation between changes from baseline to 52 weeks in forced vital capacity (fvc) \[% pred.\] and changes from baseline to 52 weeks in dyspnea score \[points\] or cough score \[points\] as measured with the living with pulmonary fibrosis (l-pf) questionnaire over 52 weeks of nintedanib treatment in patients suffering from chronic fibrosing interstitial lung disease (ild) with a progressive phenotype (excluding idiopathic pulmonary fibrosis (ipf)).


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years at visit 1 * subjects must be contractually capable and mentally able to understand and follow the instructions of the study personnel * physician's diagnosis of chronic fibrosing interstitial lung disease (ild) with a progressive phenotype, except idiopathic pulmonary fibrosis (ipf) * initiation of nintedanib as first antifibrotic therapy according to physician´s decision which has been made as part of routine care prior to and independent of study inclusion * outpatients not currently hospitalized with a life expectancy \> 12 months per investigator's assessment * written informed consent prior to study participation * current forced vital capacity (fvc) measurement (taken within the last 3 months) available in the patient file * women of childbearing potential must take appropriate precautions against getting pregnant during the intake of nintedanib. exclusion criteria: * patients with contraindications according to summary of product characteristics (smpc) * prior use of any antifibrotic treatment * lack of informed consent * pregnant or lactating females * any physician diagnosed exacerbation of interstitial lung disease (ild) in the patient's history file, irrespective of time since event * current diagnosis of lung cancer * respiratory failure (ph \ 30/min) in the patient's history * participation in a parallel interventional clinical trial * patients being spouse or lateral relatives to the second degree or economically dependent from the investigator
study of a new protease inhibitor, bms-232632, in combination with other anti-hiv drugs

Conditions: HIV Infections

Summary: the purpose of this study is to evaluate a new protease inhibitor known as bms-232632. this drug will be given in combination with 2 other anti-hiv drugs (stavudine and didanosine). the effectiveness of bms-232632 against hiv infection will be compared to that of nelfinavir, a protease inhibitor that is already commonly prescribed.

patients are randomized to receive one of two drug regimens: bms-232632, ddi, and d4t or nfv, ddi, and d4t. three different doses of bms-232632 are used in this study. randomization is stratified for hiv rna level (less than 30,000 copies/ml versus 30,000 or greater copies/ml). patients remain on their drug regimen for 48 weeks.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * have an hiv blood level between 2,000 and 200,000 copies/ml. * have a cd4 cell count of at least 100 cells/mm3. * are 18 years of age or older. * are available for follow-up for at least 48 weeks. * agree to use a barrier method of birth control (such as condoms) during the study. exclusion criteria patients will not be eligible for this study if they: * have ever received anti-hiv (antiretroviral) treatment. * have an hiv-related opportunistic infection or condition at the time of study entry. * have primary hiv infection, meaning they have recently been infected. * have had severe diarrhea within the 30 days before study entry. * have hemophilia. * have a history of pancreatitis, hepatitis, or a peripheral neuropathy. * are unable to tolerate oral medication. * are pregnant or breast-feeding. * abuse alcohol or drugs.

Keywords: didanosine dose-response relationship, drug drug therapy, combination stavudine hiv protease inhibitors reverse transcriptase inhibitors anti-hiv agents nelfinavir
influence of nutrition on nasal and bronchial affliction in patients with allergy on grass-pollen

Conditions: Bronchial Hyperreactivity; Hypersensitivity; Allergy; Bronchial Asthma

Summary: the study is meant to observe the influence of nutrition on nasal and bronchial discomfort in patients with allergy on grass pollen after specific bronchial provocation. therefore, the investigators will record the patients' nutrition habits and measure the blood level of long chained polyunsaturated fatty-acids.


Eligibility criteria:
inclusion criteria: * age \>12 and \<45 years * informed consent * known allergy on grass-pollen exclusion criteria: * age \ 45 years * clinical asthma requiring regular inhalation * vital capacity \>80% * fev1 \< 75% * chronic disease * pregnancy * inhalative or systemic steroid use * substance abuse * incapability of understanding the study's purpose and performance

Keywords: grass-pollen allergy bronchial hyperreactivity asthma
intravitreal conbercept after vitrectomy

Conditions: Early Proliferative Diabetic Retinopathy

Summary: to evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early-stage proliferative diabetic retinopathy (pdr). hypothesis: intravitreal conbercept therapy may promote functional and anatomic recovery from pdr. intravitreal conbercept therapy may be a useful and safe method for improving visual outcomes of surgery for early-stage pdr.

the drug conbercept (an anti-vascular endothelial growth factors) was recently made available for management of early prolific diabetic retinopathy, but its safety and efficacy still require study. therefore, the aim is to evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early proliferative diabetic retinopathy.the patients were randomly assigned (25 eyes each group) to either treatment group and control after they provided informed consent. the treatment group received intravitreal conbercept (10 mg/ml, 0.5 mg) immediately after surgery, while the control group did not. at the time of study enrollment, physical examinations, best-corrected visual acuity (bcva), intraocular pressure and central retinal thickness will be measured and fundoscopy be performed. the patients are going to be followed up for at least 6 months via bcva measurement, fundoscopy, oct, physical examinations and postoperative complications

Eligibility criteria:
inclusion criteria: 1. we enrolled 50 eyes from 50 patients that were affected by vh as a consequence of early active pdr. 2. patients with non-clearing vh and fibrocellular proliferation without trd who underwent ppv at tianjin medical university eye hospital were included in the study. exclusion criteria: 1. a history of previous ppv; 2. severe intraoperative complications 3. postoperative silicone oil tamponade; 4. menstruation; 5. stroke, a thromboembolic event, or myocardial infarction in the previous 6. months contraindicating the withdrawal of anti-platelet and anti-coagulant medications.
the cohort study of uveitis patients

Conditions: Uveitis

Summary: this study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. this is a cohort study. the outcome of the study is the activity of inflammation and visual prognosis. the purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.


Eligibility criteria:
inclusion criteria: * the diagnosis is uveitis; the agreement of enrolling this study; exclusion criteria: * uveitis during the first month after any intraocular surgery; \<18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.
observational ambispective study on hype cups associated with hiper liner

Conditions: Hip Arthropathy

Summary: this study intend to collect data on total hip arthroplasty performed with hype cups used with conventional polyethylene liner (hiper). medical device regulation 2017/745 regulation required proper clinical data to support claims. this study is therefore intended to provide data on hype devices to comply with medical device regulation2047/745 regulation.


Eligibility criteria:
inclusion criteria: * patient was an adult at surgery, * patient implanted with hype® acetabular cup and hiper liner, * patient was followed-up at least once on retrospective part of the study, * patient's current social security affiliation is valid. exclusion criteria: * patient refuses the use of his/her personal data, * patient is unable to follow surgeon's instruction or unavailable for follow-up, * patient with contraindication to x-rays, * patient not implanted with hype® acetabular cup and hiper liner.

Keywords: total hip arthroplasty
incidence, severity and treatment of delirium in cardiac surgery patients: a before-after study

Conditions: Delirium

Summary: delirium is a common yet under diagnosed condition in hospitalized patients, and the incidence have not previously been described in danish cardiac surgery patients. the present study seeks to describe the incidence and duration of delirium in this group of patients, before and after the introduction of standardized screening tool and a guideline for treatment of delirium after cardiac surgery.

delirium is a common yet under diagnosed condition in cardiac surgery patients, and may cause prolonged cognitive impairment and increased risk of complications. patients are at risk of e.g. pulling catheters and lines and may fall attempting to get out of bed. the aging patient population present with many risk factors for developing delirium, but diagnostic tools have been few. almost 50% present with hypoactive delirium, which is often not diagnosed, nor treated correctly. to optimize effect, treatment should be initiated early, maintained until clinical improvement is observed, and then tapered gradually. recently, delirium observation screening scale (dos scale) was developed and validated in elective cardiac surgery patients in the netherlands, with interesting results. this encouraged us to evaluate the effects of systematic delirium screening and treatment in cardiac surgery patients. to our knowledge, no prior studies have evaluated use of dos scale in this context. objectives to evaluate the incidence and severity of delirium, and the effects of standardized treatment in a population of danish cardiac surgery patients.

Eligibility criteria:
inclusion criteria: * adult patients admitted for cardiac surgery at department of cardiothoracic surgery, rigshospitalet, denmark exclusion criteria: * patients under age 18, * patients that died within 24 hours after admission.

Keywords: delirium cardiac surgery dos scale